Daptomycin
Other Antibacterials
Sold as CUBICIN · CUBICIN RF
- Drug class
- Other Antibacterials
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 57
- FDA reports (12 mo)
- 1,141
Overview
Plain-language summary, compiled from the cited regulatory records
Daptomycin is a lipopeptide antibacterial medication [1]. It belongs to the drug class of other antibacterials [1].
Daptomycin is approved for treating complicated skin and skin structure infections in adult and pediatric patients aged 1 to 17 years [1]. It is also indicated for Staphylococcus aureus bloodstream infections (bacteremia) in adult patients, including those with right-sided infective endocarditis [1]. Additionally, it is approved for Staphylococcus aureus bloodstream infections in pediatric patients aged 1 to 17 years [1].
In the past 12 months, there have been 1141 adverse event reports associated with daptomycin [2]. The most frequently reported adverse events include eosinophilic pneumonia, product use in an unapproved indication, drug ineffectiveness, pneumonitis, and eosinophilia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 44 | May 15, 2026 |
| CA Canada | Health Canada | 6 | August 15, 2025 |
| US United States | FDA | 5 | May 8, 2026 |
| EU European Union | EMA | 2 | January 20, 2026 |
GBUnited Kingdom· MHRA
44 products
Uses
1). - Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). - Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.
1. - Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.
1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
CACanada· Health Canada
6 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 5 WARNINGS AND PRECAUTIONS .................................................................................
5 ADVERSE REACTIONS ................................................................................................. 12 DRUG INTERACTIONS .................................................................................................
22 DOSAGE AND ADMINISTRATION ............................................................................. 25 OVERDOSAGE ...............................................................................................................
29 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 30 STORAGE AND STABILITY ......................................................................................... 36 SPECIAL HANDLING INSTRUCTIONS ......................................................................
USUnited States· FDA
5 products
Uses
2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). 3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. 4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S.
aureus . 4 ) • Daptomycin for Injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs.
4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
1 Complicated Skin and Skin Structure Infections (cSSSI) Daptomycin for injection is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp.
EUEuropean Union· EMA
2 products
Uses
1). - Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI). - Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. 1). - Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI. 1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Drug interactions
Known interactions involving Daptomycin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB530950014 · revised September 20, 2024
- [2]Health Canada (DPD) · 02490838 · revised March 22, 2025
- [3]FDA DailyMed · 01f3f32a-fac1-4a… · revised April 19, 2023 [PDF]
- [4]European Medicines Agency · EMEA/H/C/004310 · revised January 20, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.